Gyre Therapeutics (NASDAQ:GYRE) Releases Earnings Results, Beats Expectations By $0.19 EPS

Gyre Therapeutics (NASDAQ:GYRE) released its earnings results on Thursday. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.19, Zacks reports. Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%. The firm had revenue of $32.93 million for the quarter, compared to analysts’ expectations of $28.40 million.

Gyre Therapeutics Trading Up 18.7%

GYRE stock traded up $0.75 during midday trading on Friday, hitting $4.76. The company’s stock had a trading volume of 359,716 shares, compared to its average volume of 149,986. The company has a market cap of $530.79 million, a PE ratio of -23.80 and a beta of 2.14. Gyre Therapeutics has a 12 month low of $3.97 and a 12 month high of $9.14. The firm’s 50-day moving average is $6.51 and its 200-day moving average is $6.90.

Analyst Ratings Changes

Several research firms have recently issued reports on GYRE. Zacks Research raised Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 6th. Wall Street Zen raised shares of Gyre Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Wednesday. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.